Swiss National Bank
NMRA icon

Swiss National Bank’s Neumora Therapeutics NMRA Stock Holding History

Swiss National Bank’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110,200
Closed -$1.17M – 2432
2024
Q4 		$1.17M Buy
+110,200
New +$1.32M ﹤0.01% 2135

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Swiss National Bank's NMRA Position: Q1 2025 in Review

Swiss National Bank sold out of Neumora Therapeutics (NMRA) in Q1 2025, closing a stake of 110,200 shares — an estimated $1.17M sold.

Swiss National Bank first reported a position in NMRA in Q4 2024 and held it in 1 quarter. The position peaked at $1.17M in Q4 2024. 115 funds tracked by Wall St. Rank hold NMRA as of Q1 2025.

  • Swiss National Bank reported no remaining Neumora Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 110,200 Neumora Therapeutics shares in Q1 2025, an estimated $1.17M.
  • Swiss National Bank first reported a position in Neumora Therapeutics in Q4 2024 and held it in 1 quarter.
  • Swiss National Bank's Neumora Therapeutics position peaked at $1.17M in Q4 2024.
  • 115 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.